Internal Medicine, Gastroenterology · Doylestown, PA
NPI
1912992330
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
599 W State St, Suite 200
Doylestown, PA, 18901
Phone (215) 345-6050
Groups this clinician bills Medicare through
Medicare paid, 2024
$257K
7,956 services
Medicare patients, 2024
673
Average age 74
Drug cost, 2024
$920K
1,319 prescriptions
Company payments, 2025
$552
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alan W Chang was code 99213 (office e&m - established), 251 times for 210 patients. In total Alan W Chang billed 7,956 services in 43 codes, and Medicare paid $257K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 251 | 210 | $68.37 | $17K |
| 45380 Lower GI Endoscopy - Other | Facility | 160 | 160 | $91.57 | $15K |
| 45385 Colonoscopy - Lesion Removal | Facility | 142 | 141 | $212.26 | $30K |
| 99214 Office E&M - Established | Office | 126 | 115 | $97.54 | $12K |
| 43239 Upper GI Endoscopy | Facility | 99 | 97 | $72.93 | $7,220 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 82 | 78 | $13.12 | $1,076 |
| 99232 Hospital E&M - Subsequent | Facility | 81 | 54 | $62.47 | $5,060 |
| 99203 Office E&M - New | Office | 72 | 72 | $81.06 | $5,836 |
| 99231 Hospital E&M - Subsequent | Facility | 66 | 57 | $37.77 | $2,493 |
| 99222 Hospital E&M - Initial | Facility | 63 | 62 | $102.88 | $6,482 |
| 99204 Office E&M - New | Office | 42 | 42 | $124.65 | $5,235 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 32 | 32 | $176.04 | $5,633 |
| 45378 Lower GI Endoscopy - Other | Facility | 17 | 17 | $142.61 | $2,424 |
| 43249 Upper GI Endoscopy | Facility | 12 | 11 | $80.11 | $961 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 11 | 11 | $185.66 | $2,042 |
By year: 2022 $319K for 9,817 services; 2023 $304K for 10,648 services; 2024 $257K for 7,956 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alan W Chang prescribed most often to Medicare patients was Omeprazole, with 342 prescriptions and refills. In total Alan W Chang wrote 1,319 Medicare prescriptions that cost $920K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 342 | 809 | 102 | $2,845 |
| Pantoprazole Sodium Generic | 166 | 440 | 59 | $1,641 |
| Famotidine Generic | 153 | 345 | 50 | $1,248 |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 99 | 99 | 98 | $16K |
| Linzess Linaclotide | 46 | 64 | 12 | $33K |
| Sucralfate Generic | 37 | 52 | 13 | $771 |
| Mesalamine Generic | 37 | 91 | 11 | $10K |
| Esomeprazole Magnesium Generic | 35 | 79 | 11 | $1,109 |
| Cholestyramine Cholestyramine (With Sugar) | 26 | 38 | 12 | $1,782 |
| Stelara Ustekinumab | 21 | 34 | Under 11 | $598K |
| Dicyclomine Hcl Generic | 20 | 36 | 14 | $232 |
| Dexlansoprazole Dr Dexlansoprazole | 19 | 27 | Under 11 | $5,371 |
| Mesalamine Dr Mesalamine | 17 | 29 | Under 11 | $17K |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 15 | 15 | 15 | $235 |
| Budesonide Dr Budesonide | 15 | 21 | Under 11 | $1,768 |
Brand drugs: 280 claims; generic drugs: 1,039 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alan W Chang $552 ($552 in general payments such as food, travel and fees) from 10 companies. The largest payer was Ardelyx, Inc. with $164.
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. ARDX | 3 | $164 |
| Abbvie Inc. ABBV | 7 | $130 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 3 | $63.02 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 3 | $56.5 |
| Braintree Laboratories, Inc. | 1 | $31.02 |
| Medtronic, Inc. MDT | 1 | $23.63 |
| Celltrion USA Inc. 068270.KS | 1 | $22.63 |
| Regeneron Healthcare Solutions, Inc. REGN | 1 | $22.26 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $20.3 |
| Genzyme Corporation SNY | 1 | $18.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.